Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ION582 / Ionis
NCT06914609: REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome	Not yet recruiting	3	210	NA	ION582, Placebo	Ionis Pharmaceuticals, Inc.	Angelman Syndrome	08/27	04/30
HALOS, NCT05127226 / 2021-003009-23: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome	Active, not recruiting	1/2	51	Europe, US, RoW	ION582	Ionis Pharmaceuticals, Inc., Biogen	Angelman Syndrome	03/29	03/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ION582 / Ionis
NCT06914609: REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome	Not yet recruiting	3	210	NA	ION582, Placebo	Ionis Pharmaceuticals, Inc.	Angelman Syndrome	08/27	04/30
HALOS, NCT05127226 / 2021-003009-23: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome	Active, not recruiting	1/2	51	Europe, US, RoW	ION582	Ionis Pharmaceuticals, Inc., Biogen	Angelman Syndrome	03/29	03/29